PREVIEW: Amgen dips with results due after the bell

Amgen

03/02/2026 19:34

** Amgen AMGN.O shares down 0.8% to $342 ahead of Q4 results due after the closing bell

** Shares in obesity drugmakers declined on Tuersday after Novo Nordisk NOVOb.CO forecast a sharper than expected sales decline for 2026

** Q4 adj. EPS expected at $4.73 on a 4.2% increase in revenue to $9.47 bln, per LSEG data, vs yr-ago results EPS of $4.73

** The drugmaker has met or beaten EPS estimates in seven of past eight qtrs, with most recent miss in Q2 2024

** Of the 35 analysts that cover Amgen Inc, the breakdown of recommendations are 17 "strong buy" or "buy," 15 "hold" and 3 "sell" or "strong sell" ratings

** Median price target of $335 is up from $327.50 a month ago

** AMGN shares up 4.2% YTD stock performance vs 1.7% gain in Dow Industrials .DJI

 (Reporting by Chuck Mikolajczak)

 ((charles.mikolajczak@tr.com; @chuckmik.bsky.social))